This study compared outcomes of Mohs surgery for melanoma performed with and without MART-1 immunostains. Use of MART-1 was associated with improved margin assessment accuracy and may reduce recurrence rates, supporting routine use of melanocyte immunostains in Mohs for melanoma.

MART-1 immunostaining during Mohs surgery for melanoma improves margin assessment accuracy and is associated with better outcomes.

Routine use of melanocyte immunostains should be considered standard practice when performing Mohs for melanoma.